临床医学工程2024，Vol.31Issue(6)：671-672,2.DOI:10.3969/j.issn.1674-4659.2024.06.0671
沙利度胺联合强的松治疗重度溃疡性结肠炎患者的临床研究
Clinical Study on Thalidomide Combined with Prednisone in the Treatment of Patients with Severe Ulcerative Colitis
摘要
Abstract
Objective To explore the clinical effect of thalidomide combined with prednisone in the treatment of patients with severe ulcerative colitis(UC).Methods A total of 120 patients with severe UC admitted to our hospital from January 2021 to December 2022 were selected and randomly divided into two groups,with 60 cases in each group.The reference group was treated with prednisone,and the study group was treated with thalidomide on the basis of the reference group.The therapeutic effect,inflammatory factor levels and adverse reactions were compared between the two groups.Results The total effective rate of treatment in the study group was 83.33％,significantly higher than 58.33％in the reference group(P＜0.05).After treatment,the levels of serum IL-2 and IFN-y in the study group were significantly lower than those in the reference group,and the levels of IL-4 and IL-10 were significantly higher than those in the reference group(P＜0.05).No significant difference was found in the total incidence of adverse reactions between the study group and the reference group(15.00％vs.13.33％,P＞0.05).Conclusions Thalidomide combined with prednisone in the treatment of severe UC has significant effect and high safety,which can obviously relieve patients'inflammatory reaction.关键词
重度溃疡性结肠炎/沙利度胺/强的松/治疗效果/炎性因子/不良反应Key words
Severe ulcerative colitis/Thalidomide/Prednisone/Therapeutic effect/Inflammatory factor/Adverse reaction分类
医药卫生引用本文复制引用
董戴源,张兰芳,郭晓鹤..沙利度胺联合强的松治疗重度溃疡性结肠炎患者的临床研究[J].临床医学工程,2024,31(6):671-672,2.基金项目
河南省医学科技攻关计划联合共建项目(项目编号:LHGJ20210539) （项目编号:LHGJ20210539）
